These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36915888)

  • 41. Comprehensive pathological assessment of histological subtypes, molecular subtypes based on immunohistochemistry, and tumor-associated immune cell status in muscle-invasive bladder cancer.
    Ikeda J; Ohe C; Yoshida T; Kuroda N; Saito R; Kinoshita H; Tsuta K; Matsuda T
    Pathol Int; 2021 Mar; 71(3):173-182. PubMed ID: 33503295
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion.
    Haghayeghi K; Lu S; Matoso A; Schiff SF; Mueller-Leonhard C; Amin A
    Virchows Arch; 2021 Sep; 479(3):515-521. PubMed ID: 34218288
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of HER2 and Fascin expression on muscle-invasive bladder cancers: Classification by basaloid and luminal phenotypes.
    Arslan AI; Karabağ S; Akgül M
    Indian J Pathol Microbiol; 2022; 65(3):604-609. PubMed ID: 35900488
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
    Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
    Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.
    Blows FM; Driver KE; Schmidt MK; Broeks A; van Leeuwen FE; Wesseling J; Cheang MC; Gelmon K; Nielsen TO; Blomqvist C; Heikkilä P; Heikkinen T; Nevanlinna H; Akslen LA; Bégin LR; Foulkes WD; Couch FJ; Wang X; Cafourek V; Olson JE; Baglietto L; Giles GG; Severi G; McLean CA; Southey MC; Rakha E; Green AR; Ellis IO; Sherman ME; Lissowska J; Anderson WF; Cox A; Cross SS; Reed MW; Provenzano E; Dawson SJ; Dunning AM; Humphreys M; Easton DF; García-Closas M; Caldas C; Pharoah PD; Huntsman D
    PLoS Med; 2010 May; 7(5):e1000279. PubMed ID: 20520800
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.
    Necchi A; de Jong JJ; Raggi D; Briganti A; Marandino L; Gallina A; Bandini M; Dabbas B; Davicioni E; Capitanio U; Montorsi F; Seiler R; Wright JL; Lotan Y; Black PC; Gibb EA
    Eur Urol; 2021 Aug; 80(2):149-159. PubMed ID: 33785257
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PD-L1 Expression in Muscle-Invasive Urinary Bladder Urothelial Carcinoma According to Basal/Squamous-Like Phenotype.
    Kim B; Lee C; Kim YA; Moon KC
    Front Oncol; 2020; 10():527385. PubMed ID: 33365265
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of a Clinically Applicable NanoString-Based Gene Expression Classifier for Muscle-Invasive Bladder Cancer Molecular Stratification.
    Olkhov-Mitsel E; Yu Y; Lajkosz K; Liu SK; Vesprini D; Sherman CG; Downes MR
    Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer.
    Ottley EC; Pell R; Brazier B; Hollidge J; Kartsonaki C; Browning L; O'Neill E; Kiltie AE
    J Pathol Clin Res; 2020 Oct; 6(4):238-251. PubMed ID: 32374509
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene Assessment.
    Ecke TH; Voß PC; Schlomm T; Rabien A; Friedersdorff F; Barski D; Otto T; Waldner M; Veltrup E; Linden F; Hake R; Eidt S; Roggisch J; Heidenreich A; Rieger C; Kastner L; Hallmann S; Koch S; Wirtz RM
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887247
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Morphological and immunohistochemical characteristics of the molecular subtypes of urothelial carcinomas].
    Osmanov YI; Gaibov ZA; Kogan EA; Radenska-Lopovok SG; Tursunov KZ
    Arkh Patol; 2019; 81(5):35-44. PubMed ID: 31626203
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer.
    Wang CC; Tsai YC; Jeng YM
    PLoS One; 2019; 14(8):e0221785. PubMed ID: 31469885
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification.
    Yuk HD; Jeong CW; Kwak C; Kim HH; Moon KC; Ku JH
    BMC Cancer; 2019 Sep; 19(1):897. PubMed ID: 31500577
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular Characterization of Neuroendocrine-like Bladder Cancer.
    Batista da Costa J; Gibb EA; Bivalacqua TJ; Liu Y; Oo HZ; Miyamoto DT; Alshalalfa M; Davicioni E; Wright J; Dall'Era MA; Douglas J; Boormans JL; Van der Heijden MS; Wu CL; van Rhijn BWG; Gupta S; Grivas P; Mouw KW; Murugan P; Fazli L; Ra S; Konety BR; Seiler R; Daneshmand S; Mian OY; Efstathiou JA; Lotan Y; Black PC
    Clin Cancer Res; 2019 Jul; 25(13):3908-3920. PubMed ID: 30952638
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases.
    Bontoux C; Rialland T; Cussenot O; Compérat E
    Virchows Arch; 2021 Apr; 478(4):637-645. PubMed ID: 33128085
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
    Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S
    Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular Classification of Bladder Urothelial Carcinoma Using NanoString-Based Gene Expression Analysis.
    Lopez-Beltran A; Blanca A; Cimadamore A; Gogna R; Montironi R; Cheng L
    Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771663
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical implications of molecular subtyping in bladder cancer.
    Satyal U; Sikder RK; McConkey D; Plimack ER; Abbosh PH
    Curr Opin Urol; 2019 Jul; 29(4):350-356. PubMed ID: 31158107
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis.
    de Jong JJ; Liu Y; Robertson AG; Seiler R; Groeneveld CS; van der Heijden MS; Wright JL; Douglas J; Dall'Era M; Crabb SJ; van Rhijn BWG; van Kessel KEM; Davicioni E; Castro MAA; Lotan Y; Zwarthoff EC; Black PC; Boormans JL; Gibb EA
    Genome Med; 2019 Oct; 11(1):60. PubMed ID: 31619281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.